# Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC

> **NCT06013943** · PHASE2 · UNKNOWN · sponsor: **Eastern Hepatobiliary Surgery Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Gallbladder Cancer

## Interventions

- **DRUG:** Envafolimab+Gemox

## Key facts

- **NCT ID:** NCT06013943
- **Lead sponsor:** Eastern Hepatobiliary Surgery Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-17
- **Primary completion:** 2025-05
- **Final completion:** 2025-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06013943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06013943, "Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06013943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*